Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (GB:0EE0)
LSE:0EE0
0EE0 Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.74 - $19.13
Previous CloseN/A
Volume8.63K
Average Volume (3M)8.52K
Market Cap
$838.20M
Enterprise ValueN/A
Total Cash (Recent Filing)$367.52M
Total Debt (Recent Filing)$66.06M
Price to Earnings (P/E)―
Beta2.47
Next Earnings
Jul 31, 2025EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding54,748,497
10 Day Avg. Volume6,093
30 Day Avg. Volume8,515
Financial Highlights & Ratios
PEG Ratio-6.28
Price to Book (P/B)-89.85
Price to Sales (P/S)0.00
P/FCF Ratio-3.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$36.86Price Target Upside137.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
uniQure News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceQURE reported a net loss per share of ($0.82) vs. consensus of ($1.00), indicating better-than-expected financial performance.
Regulatory DevelopmentsQURE is on track to report initial data from the Ph1/2a study in 2H25, showing ongoing progress in their clinical trials.
Regulatory ProgressAMT-130 in Huntington’s disease (HD) remains on track for a potential accelerated approval, with the FDA recently granting Breakthrough Therapy designation.
Bears Say
Market ReactionThe recent sell-off of QURE shares is seen as overdone and driven by concerns surrounding the appointment of Dr. Vinay Prasad as head of the FDA’s Center for Biologics Evaluation and Research, as well as by investor disappointment with data from competitor HD program PTC518.
Share Price VolatilityVolatility for QURE shares has been observed over the past few months on regulatory developments.
Options Prices
Currently, No data available
---
Ownership Overview
2.71% Insiders
10.10%
Mutual Funds
1.40% Other Institutional Investors
79.68% Public Companies and Individual Investors
0EE0 FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest share price was $3.74 and its highest was $19.13 in the past 12 months.
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is $838.20M.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Jul 31, 2025 which is in 68 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on May 09, 2025. The company reported -$0.82 earnings per share for the quarter, beating the consensus estimate of -$1.001 by $0.181.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -0.9.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 54,748,497 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$0.82 in its last earnings report, beating expectations of -$1.001. Following the earnings report the stock price went up 1.501%.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in GB:0EE0
uniQure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.86 (137.65% Upside)
$36.86 (137.65% Upside)
Blogger Sentiment
Bullish
GB:0EE0 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
222.91%
12-Months-Change
Fundamentals
Return on Equity
-241.16%
Trailing 12-Months
Asset Growth
-21.38%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
0EE0 Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with significant progress in regulatory and clinical advancements, particularly with AMT-130, and a strong financial position. However, the declines in revenue and immunosuppression-related adverse events were noted as challenges.Read More>0EE0 Stock 12 Month Forecast
Average Price Target
$36.86
▲( 137.65% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Spyre Therapeutics
―
Intellia Therapeutics
―
CureVac
―
Day One Biopharmaceuticals
―